Consensus Tarsus Pharmaceuticals, Inc. Nasdaq

Equities

US87650L1035

End-of-day quote Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

06-10	Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
05-31	Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	CI

Evolution of the average Target Price on Tarsus Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e380.IwIJ01bETcgZ9TTGlLnbZIWhMOR41OvndhMbOVZ5QfI.eTo65ACmJ6tcjFX25_-LVuDUVKI9p7-dF0ppTyY-JqRpUm2He5Z6g0OARw~a14da1f697b1b1e292ebdae2d3933cd9

Analyst Recommendations on Tarsus Pharmaceuticals, Inc.

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	05-09	MT
Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	02-29	MT
Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	02-28	MT
Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	11-20	MT
HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	11-10	MT
Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	11/09/23	MT
HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	11/08/23	MT
HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	26/07/23	MT
William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	18/07/23	MT
HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $44 From $40, Keeps Buy Rating	26/06/23	MT
Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $42 From $40, Maintains Buy Rating	16/06/23	MT
Guggenheim Initiates Coverage on Tarsus Pharmaceuticals With Buy Rating, $40 Price Target	18/05/23	MT
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $43 From $66, Maintains Outperform Rating	10/11/22	MT
Barclays Starts Tarsus Pharmaceuticals at Overweight With $40 Price Target	01/08/22	MT
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $66 From $55, Keeps Outperform Rating	03/05/22	MT
HC Wainwright Starts Tarsus Pharmaceuticals at Buy With $40 Price Target	21/12/21	MT
Oppenheimer Initiates Coverage on Tarsus Pharmaceuticals With Outperform Rating, $55 Price Target	23/11/21	MT
TARSUS PHARMACEUTICALS : Raymond James Adjusts Tarsus Pharmaceuticals' Price Target to $65 from $50, Keeps Strong Buy Rating	08/10/21	MT
TARSUS PHARMACEUTICALS : Raymond James Adjusts Tarsus Pharmaceuticals' Price Target to $50 From $39, Maintains Strong Buy Rating	29/06/21	MT
TARSUS PHARMACEUTICALS : Jefferies Adjusts Price Target on Tarsus Pharmaceuticals to $45 From $35, Reiterates Buy Rating	22/06/21	MT
TARSUS PHARMACEUTICALS : Raymond James Starts Tarsus Pharmaceuticals at Strong Buy with $39 Price Target	10/11/20	MT
TARSUS PHARMACEUTICALS : BofA Securities Starts Tarsus Pharmaceuticals at Buy With $33 Price Target	10/11/20	MT
TARSUS PHARMACEUTICALS : Ladenburg Thalmann Starts Tarsus Pharmaceuticals at Buy With $42 Price Target	10/11/20	MT
TARSUS PHARMACEUTICALS : Jefferies & Co Initiates Coverage on Tarsus Pharmaceuticals With Buy Rating, $35 Price Target	10/11/20	MT